SENORES PHARMACEUTICALS L Net Assets
SENORES PHARMACEUTICALS L net assets. Based on the latest financial reports, SENORES PHARMACEUTICALS L (SENORES) has net assets worth Rs9.65 Billion INR (≈ $104.31 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs16.04 Billion ≈ $173.45 Million USD) and total liabilities (Rs6.39 Billion ≈ $69.13 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore SENORES PHARMACEUTICALS L (SENORES) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs9.65 Billion |
| % of Total Assets | 60.14% |
| Annual Growth Rate | 126.59% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4310.39 |
Net Assets of SENORES PHARMACEUTICALS L (2022–2026)
Net assets of SENORES PHARMACEUTICALS L from 2022 to 2026. This chart illustrates how SENORES PHARMACEUTICALS L's net assets have evolved over time, based on quarterly financial data. See SENORES equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for SENORES PHARMACEUTICALS L (2022–2026)
The table below shows the annual net assets of SENORES PHARMACEUTICALS L from 2022 to 2026. For live market cap and overall valuation, see SENORES stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs9.65 Billion ≈ $104.31 Million |
+10057.66% |
| 2025-03-31 | Rs94.96 Million ≈ $1.03 Million |
-95.90% |
| 2024-03-31 | Rs2.32 Billion ≈ $25.06 Million |
+409.26% |
| 2023-03-31 | Rs454.99 Million ≈ $4.92 Million |
+24.35% |
| 2022-03-31 | Rs365.90 Million ≈ $3.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SENORES PHARMACEUTICALS L's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
SENORES PHARMACEUTICALS L Net Assets Breakdown (March 2026)
SENORES PHARMACEUTICALS L net assets breakdown by equity component as of March 2026.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Rs460.50 Million | 4.93% |
| Other Components | Rs8.88 Billion | 95.07% |
| Total Equity | Rs9.34 Billion | 100.00% |
SENORES PHARMACEUTICALS L Competitors by Market Cap
The table below lists competitors of SENORES PHARMACEUTICALS L ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rashi Peripherals Limited
NSE:RPTECH
|
$571.28 Million |
|
Zhejiang Meili High Technology Co Ltd
SHE:300611
|
$571.41 Million |
|
Jilin Liyuan Precision Manufacturing Co Ltd
SHE:002501
|
$571.42 Million |
|
Perusahaan Perkebunan London Sumatra Indonesia Tbk PT
JK:LSIP
|
$571.46 Million |
|
Hanwha Investment&Securities Co Ltd
KO:003530
|
$571.05 Million |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
|
$571.00 Million |
|
ZJAMP Group Co Ltd
SHE:002758
|
$570.90 Million |
|
Cuckoo Electronics Co Ltd
KO:192400
|
$570.76 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SENORES PHARMACEUTICALS L's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 7,861,900,000 to 9,336,000,000, a change of 1,474,100,000 (18.7%).
- Net income of 1,153,800,000 contributed positively to equity growth.
- Share repurchases of 19,100,000 reduced equity.
- New share issuances of 236,200,000 increased equity.
- Other factors increased equity by 103,200,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs1.15 Billion | +12.36% |
| Share Repurchases | Rs19.10 Million | -0.2% |
| Share Issuances | Rs236.20 Million | +2.53% |
| Other Changes | Rs103.20 Million | +1.11% |
| Total Change | Rs- | 18.75% |
Book Value vs Market Value Analysis
This analysis compares SENORES PHARMACEUTICALS L's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 144.37x to 5.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | Rs7.95 | Rs1147.00 | x |
| 2023-03-31 | Rs9.88 | Rs1147.00 | x |
| 2024-03-31 | Rs44.35 | Rs1147.00 | x |
| 2025-03-31 | Rs216.18 | Rs1147.00 | x |
| 2026-03-31 | Rs213.54 | Rs1147.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SENORES PHARMACEUTICALS L utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.36%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.24%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.72x
- Recent ROE (12.36%) is above the historical average (9.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 2.71% | 7.04% | 0.24x | 1.62x | Rs-26.68 Million |
| 2023 | 18.53% | 23.87% | 0.27x | 2.88x | Rs38.83 Million |
| 2024 | 15.40% | 14.92% | 0.34x | 3.04x | Rs110.23 Million |
| 2025 | 0.09% | 0.18% | 26.28x | 0.02x | Rs-779.34 Million |
| 2026 | 12.36% | 18.24% | 0.39x | 1.72x | Rs220.20 Million |
Industry Comparison
This section compares SENORES PHARMACEUTICALS L's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $7,848,618,806
- Average return on equity (ROE) among peers: 25.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SENORES PHARMACEUTICALS L (SENORES) | Rs9.65 Billion | 2.71% | 0.66x | $571.27 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $18.21 Billion | 5.12% | 0.72x | $4.72 Billion |
| NGL Fine-Chem Limited (NGLFINE) | $136.48 Million | 19.82% | 0.86x | $171.12 Million |
| Pfizer Limited (PFIZER) | $21.18 Billion | 14.40% | 0.38x | $1.89 Billion |
| Sanofi India Limited (SANOFI) | $4.22 Billion | 35.20% | 0.35x | $842.25 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.73 Billion | 66.30% | 0.58x | $870.71 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $620.96 Million | 12.68% | 1.22x | $139.94 Million |
About SENORES PHARMACEUTICALS L
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, ne… Read more